- Title
- 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
- Creators
- A. Oaknin - Vall d'Hebron Institute of OncologyE. Prendergast - Minnesota OncologyV. Salutari - Università Cattolica del Sacro CuoreR. Littell - Kaiser PermanenteM. Schenker - Department of Medical Oncology, Sf. Nectarie Oncology Center Craiova, Craiova, RomaniaJ. Martinez-Garcia - Hospital Universitario Virgen de la ArrixacaF. Ueland - University of KentuckyJ-Y. Lee - Severance HospitalR. De Vivo - Department of Oncology, Ospedale San Bartolo, Vicenza, ItalyO. Yeku - Harvard Medical SchoolA. Dean - St John of God Subiaco HospitalT. Bese - Gynecologic Oncology, Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, TürkiyeA. Jewell - University of Kansas Medical CenterT. Van Gorp - Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Leuven Cancer Institute, University Hospitals, Leuven, BelgiumJ. Diaz - Baptist Health South FloridaL. Maloney - Clinical Development, pharma& GmbH, New York, United States of AmericaK. Fujiwara - Saitama Medical UniversityR. Kristeleit - Guy's and St Thomas' NHS Foundation TrustB.J. Monk - Florida Cancer Specialists & Research Institute
- Publication Details
- ESMO open, Vol.10
- Publisher
- Elsevier Ltd
- Identifiers
- 991006176539802656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
ESMO open, Vol.10
06/2025
Metrics
1 Record Views